Analysis of the quality of life of patients with metastatic desopathic prostate cancer treated with kabatha.

In the CARD study, cabazitaxel (cabataxel) significantly extended the progressive survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors compared to abitor or erythromycin.
1. In the CARD study, kabazito significantly improved the progression-free survival and total survival rates of patients with metastatic desopathic prostate cancer compared to abitretone or nzarusamine, compared to patients previously treated with dositone and alternative androgen signaling target inhibitors.
is now a summary of the quality of life prognossing of card studies.
photo source: ThelancetCARD is a randomized, open-label phase 4 study involving 62 clinical sites in 13 European countries.
patients who will be diagnosed with metastatic desopathic resistance to prostate cancer (age ≥18, Oriental Cooperative Oncology Group (ECOG) Performance Status ≤2) are randomly assigned (1:1) through an interactive voice network response system to receive the Kabata team (25 mg/m2, static drops, 3 once a week; strong pine, 10 mg/day and granulocyte set stimulation factor) with a bittron group (1000 mg/day plus strong pine 5 mg.2/day) or enrugrumamine group (160 mg/day, oral).
end point is progress-free survival.
the results were ECOG performance status, the progression time of the disease of the previous androgen signal target inhibitor, and the time of the previous androgen signal target inhibitor.
Photo Source: Life science's primary endpoint is imaging progression-free survival, where we provide more detailed pain analysis and pre-planned patient report results, evaluated using the Prostate Cancer Treatment Function Assessment Questionnaire (FACT-P) and the European Quality of Life 5 Dimension 5 Level Scale (EQ-5D-5L).
analysis of the efficacy of intentionally treated populations was carried out.
Baseline analysis of pain response in intended treatment populations and baseline post-assessment of at least one BPI-SF project 3, patient reported results (PROs) baseline analysis and at least one post-baseline assessment of FACT-P or EQ-5D-5L (pro-population) in intentional treatment populations.
card study was registered on ClinicalTrials.gov (NCT02485691) and analyzed bone-related events in people intended to be treated.
2, progress comparison Based on the study, we screened 303 patients, 255 of whom were randomly assigned to the kabata group (n=129) or the Abitron/Enrugrumam group (n=126).
follow-up time was 9.2 months (IQR 5.6-13.1).
51 (46%) of the 111 kabata group had a pain response, and 21 (19%) of the 109 abitron/ensyruamine group had a pain response (p.lt;0.0001).
the mid-level pain progression time (NE; 95% CI NE-NE) in the Kabata and Abitron/Enrugrumic groups is inestimable (risk ratio of 0.55, 95% confidence interval 0.32-0.97; pair rank p=0.035).
the time of symptomatic bone events was 16.7 months (10.8-NE) in the NE (95% confidence interval 20.0-NE) and 16.7 months (10.8-NE) in the abitron/ensergide group (HR 0.59, 95% CI 0.35-1.01;
of the total ACT-P score deterioration in the Kabata group was 14.8 months (95 per cent confidence interval 6.3-NE), while the Abitron/Enrugrumam group was 8.9 months (HR 0.72,95% CI 0.44-1.20, p=0.21).
In terms of changes in EQ-5D-5L utility index scores at baseline check-ups, kabatasai had a significant effect on treatment compared to the abitron/ensergide group (p-0.030), but in the EQ-5D-5L visual simulation table, there was no difference between the treatment group and the baseline examination (p-0.060).
3. Summary of this study shows that kabathal improves pain relief, delays pain progression, and the time of bone symptoms, as well as the EQ-5D-5L utility index score, i.e., kabathal does not degrade quality of life compared to the use of second-generation androgen signal target inhibitors.
References: . Ozge Cevik; Hilal Acidereli; Fatma Aysun Turut; Sahin Yildirim; Ceyda Acilan.Cabazitaxel exhibits more than fair molecular changes compared to other taxanes in androgen-independent cancer prostate cells. (J) Journal of Biochemical and Molecular Toxicology.2020. Angelos Koutras; Flora Zagouri; Georgia-Angeliki Koliou; Elizabeth Psoma; Ioannis Chryssogonidis; Georgios Lazaridis; Dimitrios Tryfonopoulos; Athanasios Kotsakis; Eleni Res; Nikolaos K. Kentepozidis; Evangelia Razis; Amanda Psyrri; Georgios Koumakis; Haralabos P. Kalofonos; Meletios A. Dimopoulos; George Fountzilas.Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. (J) British Journal of Cancer.2020. Li Zequn; Xuan Zefeng; Chen Jian; Song Wenfeng; Zhang Shiyu; Jin Cheng; Zhou Mengqiao; Zheng Shusen; Song Penghong.Inhibiting the NF-B pathway enhances the antitumor effect of cabazitaxel by downregulating Bcl-2 in pancreatic cancer. (J) International journal of oncology.2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (J) Der Urologe: Organ der Deutschen Gesellschaft für Urologie Organ des Berufsverbandes der Deutschen Urologen.2020.